MX2020004811A - Métodos y composiciones de reconstrucción no mieloablativa de médula ósea. - Google Patents
Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.Info
- Publication number
- MX2020004811A MX2020004811A MX2020004811A MX2020004811A MX2020004811A MX 2020004811 A MX2020004811 A MX 2020004811A MX 2020004811 A MX2020004811 A MX 2020004811A MX 2020004811 A MX2020004811 A MX 2020004811A MX 2020004811 A MX2020004811 A MX 2020004811A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- bone marrow
- compositions
- marrow reconstitution
- myeloablative
- Prior art date
Links
- 210000001185 bone marrow Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001400 myeloablative effect Effects 0.000 title abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
La descripción hace referencia, en términos generales, a métodos y composiciones para realizar trasplantes de médula ósea usando un agente quimioterapéutico no mieloablativo y células resistentes a agentes quimioterapéuticos. Usando los métodos y las composiciones que se describen en la presente, es posible reconstituir la médula ósea de un paciente y el paciente evita los efectos secundarios adversos, incluidos la mieloablación y/o una alteración del sistema inmunológico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762586813P | 2017-11-15 | 2017-11-15 | |
PCT/US2018/061211 WO2019099619A1 (en) | 2017-11-15 | 2018-11-15 | Methods and compositions for non-myeloablative bone marrow reconstitution |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004811A true MX2020004811A (es) | 2020-10-07 |
Family
ID=66539907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004811A MX2020004811A (es) | 2017-11-15 | 2018-11-15 | Métodos y composiciones de reconstrucción no mieloablativa de médula ósea. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190269734A1 (es) |
EP (1) | EP3710013A4 (es) |
JP (1) | JP2021503015A (es) |
KR (1) | KR20200089289A (es) |
CN (1) | CN111417407A (es) |
AU (1) | AU2018367546A1 (es) |
BR (1) | BR112020009377A2 (es) |
CA (1) | CA3082404A1 (es) |
IL (1) | IL274632A (es) |
MX (1) | MX2020004811A (es) |
SG (1) | SG11202004145QA (es) |
WO (1) | WO2019099619A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
EP4096649A4 (en) * | 2020-01-31 | 2024-04-17 | G Tech Bio Llc | COMPOSITIONS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS |
US20220241326A1 (en) * | 2021-02-01 | 2022-08-04 | Serhat Gumrukcu | Compositions and methods for providing chemoprotective effects |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109168A0 (en) * | 1993-04-01 | 1994-06-24 | Univ Columbia | A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs |
DE60238486D1 (de) * | 2001-07-10 | 2011-01-13 | Johnson & Johnson Res Pty Ltd | Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen |
US7737124B2 (en) * | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
US20100129329A1 (en) * | 2006-11-08 | 2010-05-27 | Aldagen, Inc. | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION |
WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
WO2011008348A2 (en) * | 2009-07-15 | 2011-01-20 | Calimmune Inc. | Dual vector for inhibition of human immunodeficiency virus |
WO2013093919A2 (en) * | 2011-12-22 | 2013-06-27 | Yeda Research And Development Co. Ltd. | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
AU2013204327B2 (en) * | 2012-04-20 | 2016-09-01 | Aviagen | Cell transfection method |
WO2014165825A2 (en) * | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
-
2018
- 2018-11-15 US US16/191,816 patent/US20190269734A1/en active Pending
- 2018-11-15 KR KR1020207016902A patent/KR20200089289A/ko unknown
- 2018-11-15 EP EP18879410.1A patent/EP3710013A4/en active Pending
- 2018-11-15 MX MX2020004811A patent/MX2020004811A/es unknown
- 2018-11-15 CN CN201880077273.2A patent/CN111417407A/zh active Pending
- 2018-11-15 JP JP2020545238A patent/JP2021503015A/ja active Pending
- 2018-11-15 CA CA3082404A patent/CA3082404A1/en active Pending
- 2018-11-15 AU AU2018367546A patent/AU2018367546A1/en active Pending
- 2018-11-15 WO PCT/US2018/061211 patent/WO2019099619A1/en unknown
- 2018-11-15 SG SG11202004145QA patent/SG11202004145QA/en unknown
- 2018-11-15 BR BR112020009377-7A patent/BR112020009377A2/pt unknown
-
2020
- 2020-05-13 IL IL274632A patent/IL274632A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200089289A (ko) | 2020-07-24 |
WO2019099619A1 (en) | 2019-05-23 |
IL274632A (en) | 2020-06-30 |
CA3082404A1 (en) | 2019-05-23 |
US20190269734A1 (en) | 2019-09-05 |
EP3710013A1 (en) | 2020-09-23 |
CN111417407A (zh) | 2020-07-14 |
EP3710013A4 (en) | 2021-06-16 |
JP2021503015A (ja) | 2021-02-04 |
SG11202004145QA (en) | 2020-06-29 |
BR112020009377A2 (pt) | 2020-11-24 |
AU2018367546A1 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004811A (es) | Métodos y composiciones de reconstrucción no mieloablativa de médula ósea. | |
ES2544967T3 (es) | Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas | |
HN2011001195A (es) | Compuestos que expanden las celulas madre hematopoieticas | |
CO2020003478A2 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
CL2019003800A1 (es) | Métodos para tratar la enfermedad de huntington. | |
BR112018003031A2 (pt) | formulações clínicas | |
AR107242A1 (es) | Preparación térmica de esporas bacterianas | |
ES2572211T3 (es) | Regeneración de músculo esquelético utilizando células madre mesenquimales | |
CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
MX2019008872A (es) | Prevencion y tratamiento de da?o o enfermedad osea y cartilago. | |
CL2019000732A1 (es) | Tratamiento avv de la enfermedad de huntington. | |
IN2015DN02729A (es) | ||
CL2018000963A1 (es) | Cosmética que tiene bacterias probióticas | |
CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
BR112019007815A2 (pt) | composição de curativo tópico e método de preparação do mesmo para o tratamento de tecido de pele danificado | |
MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
CR20150310A (es) | Solución para preservar conductos vasculares | |
ECSP20024456A (es) | Uso de composiciones que contienen Streptomyces melanosporofaciens AGL225 en el control de enfermedades de las plantas | |
CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
AR115081A1 (es) | Aislados de microbacterias y sus usos | |
MX2020004063A (es) | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. | |
BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
PH12015502827A1 (en) | Methods and compositions for enhancing stem cell mobilization | |
CO2017010151A2 (es) | Material de implante compuesto |